In addition, studies have confirmed that SLC38A4 is a prospective biomarker with therapeutic goal that exerts tumor suppressive effects in hepatocellular carcinoma by modulating the Wnt/β-catenin/MYC/HMGCS2 axis [35]. Here, HMGCS2 is linked to hepatocellular carcinoma.